Literature DB >> 8941128

Electrical remodeling in atrial fibrillation. Time course and mechanisms.

A Goette1, C Honeycutt, J J Langberg.   

Abstract

BACKGROUND: Atrial fibrillation is self-perpetuating, suggesting that the tachyarrhythmia causes electrophysiological changes that contribute to the progressive nature of the disease. In animal models, pacing-induced rapid atrial rates result in sustained atrial fibrillation. This is mediated by shortening of refractory periods termed electrical remodeling. The purpose of the present study was to characterize the time course of electrical remodeling and to define mechanisms of the phenomenon. METHODS AND
RESULTS: Closed-chest dogs were anesthetized, pretreated with atropine and propranolol, and subjected to 7 hours of atrial pacing at 800 bpm. The effective and absolute refractory periods (ARP and ERP) were measured during and after rapid pacing, and transvenous endocardial biopsy specimens were examined using electron microscopy. Despite autonomic blockade and the absence of change in right atrial pressure, persistent atrial tachycardia caused ARP and ERP to fall by > 10%. Electrical remodeling developed quickly, with more than half of the phenomenon occurring during the first 30 minutes of high-rate pacing. Pretreatment with glibenclamide in doses sufficient to block the ATP-sensitive potassium current had no effect. Atrial electrical remodeling was blocked by verapamil and accentuated by hypercalcemia. Biopsy specimens from controls subjected to rapid pacing showed mitochondrial swelling consistent with calcium overload. Biopsies from verapamil-treated animals were normal.
CONCLUSIONS: Atrial electrical remodeling develops quickly, is progressive, and may be persistent. Shifts in autonomic tone, atrial stretch, or depletion of high-energy phosphates do not contribute significantly to the phenomenon. Results of the study suggest that atrial electrical remodeling is mediated by rate-induced intracellular calcium overload.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8941128     DOI: 10.1161/01.cir.94.11.2968

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  93 in total

Review 1.  Lessons learnt from multisite pacing for AF management-technical challenges.

Authors:  R Mehra; B Kaemmerer; S Fitts
Journal:  J Interv Card Electrophysiol       Date:  2000-01       Impact factor: 1.900

2.  External cardioversion of atrial fibrillation: role of paddle position on technical efficacy and energy requirements.

Authors:  G L Botto; A Politi; W Bonini; T Broffoni; R Bonatti
Journal:  Heart       Date:  1999-12       Impact factor: 5.994

Review 3.  Science, medicine, and the future: Radiofrequency ablation for atrial fibrillation.

Authors:  N R Grubb; S Furniss
Journal:  BMJ       Date:  2001-03-31

4.  Effects of pretreatment with verapamil on early recurrences after electrical cardioversion of persistent atrial fibrillation: a randomised study.

Authors:  E Bertaglia; D D'Este; A Zanocco; F Zerbo; P Pascotto
Journal:  Heart       Date:  2001-05       Impact factor: 5.994

5.  Acute pressure overload cardiac arrhythmias are dependent on the presence of myocardial tissue catecholamines.

Authors:  A J Drake-Holland; M I Noble; M J Lab
Journal:  Heart       Date:  2001-05       Impact factor: 5.994

6.  Inhibitory effects of JTV-519, a novel cardioprotective drug, on potassium currents and experimental atrial fibrillation in guinea-pig hearts.

Authors:  H Nakaya; Y Furusawa; T Ogura; M Tamagawa; H Uemura
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

Review 7.  Low-voltage-activated ("T-Type") calcium channels in review.

Authors:  Anne Marie R Yunker; Maureen W McEnery
Journal:  J Bioenerg Biomembr       Date:  2003-12       Impact factor: 2.945

Review 8.  Proteomics and transcriptomics in atrial fibrillation.

Authors:  Marc Sühling; Carmen Wolke; Christian Scharf; Uwe Lendeckel
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2018-01-09

9.  Sinus rhythm maintenance following DC cardioversion of atrial fibrillation is not improved by temporary precardioversion treatment with oral verapamil.

Authors:  C-J A Lindholm; O Fredholm; S-J Möller; N Edvardsson; T Kronvall; T Pettersson; V Firsovaite; A Roijer; C J Meurling; P G Platonov; S B Olsson
Journal:  Heart       Date:  2004-05       Impact factor: 5.994

Review 10.  Is there a future for antiarrhythmic drug therapy?

Authors:  P G Guerra; M Talajic; D Roy; M Dubuc; B Thibault; S Nattel
Journal:  Drugs       Date:  1998-11       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.